RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
JHL Biotech, a China-Taiwan biosimilar company, placed $106 million in convertible bonds in a financing led by VMS Investment Group, a Hong Kong PE firm. The round was joined by existing shareholders. JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio. Earlier this year, JHL completed a voluntary de-listing of its Taiwan shares, a transaction that allowed shareholders to retain ownership of their holdings. The company is expected to conduct a $250 million IPO in Hong Kong later this year.
Source: China Biotoday
